Gene expression in chorionic villous samples at 11 weeks of gestation in women who develop pre‐eclampsia later in pregnancy: implications for screening

Farina, Antonio; Zucchini, Cinzia; Sanctis, Paola De; Morano, Danila; Sekizawa, Akihiko; Purwosunu, Yuditiya; Okai, Takashi; Rizzo, Nicola

doi:10.1002/pd.2675

Cited by 27 publications

(21 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…25 Previous studies have reported that it is possible to assess gene expression differences in first trimester placentae from pregnancies with known outcomes, well before clinical disease symptoms or developmental abnormalities are apparent. [26][27][28][29][30][31][32] The results of this study correlate with our previous findings in which we have demonstrated a significant reduction in placental BGN from human pregnancies complicated by FGR collected at third trimester gestation compared with gestation-matched controls. 18 The results from this study support a temporal relationship between reduced BGN expression and SGA/FGR and, therefore, suggest a causal role for placental BGN in the success of pregnancy outcome.…”

Section: Discussionsupporting

confidence: 81%

Expression of Biglycan in First Trimester Chorionic Villous Sampling Placental Samples and Altered Function in Telomerase-Immortalized Microvascular Endothelial Cells

Chui

Gunatillake

Brennecke

et al. 2017

ATVB

View full text Add to dashboard Cite

Objective— Biglycan (BGN) has reduced expression in placentae from pregnancies complicated by fetal growth restriction (FGR). We used first trimester placental samples from pregnancies with later small for gestational age (SGA) infants as a surrogate for FGR. The functional consequences of reduced BGN and the downstream targets of BGN were determined. Furthermore, the expression of targets was validated in primary placental endothelial cells isolated from FGR or control pregnancies. Approach and Results— BGN expression was determined using real-time polymerase chain reaction in placental tissues collected during chorionic villous sampling performed at 10 to 12 weeks’ gestation from pregnancies that had known clinical outcomes, including SGA. Short-interference RNA reduced BGN expression in telomerase-immortalized microvascular endothelial cells, and the effect on proliferation, angiogenesis, and thrombin generation was determined. An angiogenesis array identified downstream targets of BGN, and their expression in control and FGR primary placental endothelial cells was validated using real-time polymerase chain reaction. Reduced BGN expression was observed in SGA placental tissues. BGN reduction decreased network formation of telomerase-immortalized microvascular endothelial cells but did not affect thrombin generation or cellular proliferation. The array identified target genes, which were further validated: angiopoetin 4 ( ANGPT4 ), platelet-derived growth factor receptor α ( PDGFRA ), tumor necrosis factor superfamily member 15 ( TNFSF15 ), angiogenin ( ANG ), serpin family C member 1 ( SERPIN1 ), angiopoietin 2 ( ANGPT2 ), and CXC motif chemokine 12 ( CXCL12 ) in telomerase-immortalized microvascular endothelial cells and primary placental endothelial cells obtained from control and FGR pregnancies. Conclusions— This study reports a temporal relationship between altered placental BGN expression and subsequent development of SGA. Reduction of BGN in vascular endothelial cells leads to disrupted network formation and alterations in the expression of genes involved in angiogenesis. Therefore, differential expression of these may contribute to aberrant angiogenesis in SGA pregnancies.

show abstract

Section: Discussionsupporting

confidence: 81%

Expression of Biglycan in First Trimester Chorionic Villous Sampling Placental Samples and Altered Function in Telomerase-Immortalized Microvascular Endothelial Cells

Chui

Gunatillake

Brennecke

et al. 2017

ATVB

View full text Add to dashboard Cite

show abstract

“…These data and other similar data obtained at a time in pregnancy when what is considered the root cause of preeclampsia is occurring should provide insights and perhaps useful predictors for preeclampsia. [90, 91] It might also be feasible to use these markers to contribute to the understanding of early mechanisms in preeclampsia. Unfortunately we found no study including placental samples from FGR obtained in early pregnancy, thus the question of similarities or differences between FGR and preeclampsia cannot be addressed.…”

Section: Genomics and Proteomicsmentioning

confidence: 99%

The placenta in preeclampsia

Roberts

Escudero

2012

Pregnancy Hypertension: An International Journal of Women's Car

358

249

View full text Add to dashboard Cite

The root cause of preeclampsia is the placenta. Preeclampsia begins to abate with the delivery of the placenta and can occur in the absence of a fetus but with the presence of trophoblast tissue with hydatidiform moles. In view of this, study of the placenta should provide insight into the pathophysiology of preeclampsia. In this presentation we examine placental pathological and pathophysiological changes with preeclampsia and fetal growth restriction (FGR). It would seem that this comparison should be illuminating as both conditions are associated with similarly abnormal placentation yet only in preeclampsia is there a maternal pathophysiological syndrome. Similar insights about early and late onset preeclampsia should also be provided by such information. We report that the placental abnormalities in preeclampsia are what would be predicted in a setting of reduced perfusion and oxidative stress. However, the differences from FGR are inconsistent. The most striking differences between the two conditions are found in areas that have been the least studied. There are differences between the placental findings in early and late onset preeclampsia but whether these are qualitative, indicating different diseases, or simply quantitative differences within the same disease is difficult to determine. We attempt to decipher the true differences, seek an explanation for the disparate results and provide recommendations that we hope may help resolve these issues in future studies.

show abstract

“…IL-8 gene expression is also altered in first-trimester trophoblasts derived from women developing PE later (Farina et al, 2011 …”

Section: Il8mentioning

confidence: 99%

Expression Profile of C19MC microRNAs in Placental Tissue in Pregnancy-Related Complications

Hromadníková

Kotlabova

Ondráčková

et al. 2015

DNA and Cell Biology

106

View full text Add to dashboard Cite

Gene expression in chorionic villous samples at 11 weeks of gestation in women who develop pre‐eclampsia later in pregnancy: implications for screening

Cited by 27 publications

References 42 publications

Expression of Biglycan in First Trimester Chorionic Villous Sampling Placental Samples and Altered Function in Telomerase-Immortalized Microvascular Endothelial Cells

Expression of Biglycan in First Trimester Chorionic Villous Sampling Placental Samples and Altered Function in Telomerase-Immortalized Microvascular Endothelial Cells

The placenta in preeclampsia

Expression Profile of C19MC microRNAs in Placental Tissue in Pregnancy-Related Complications

Contact Info

Product

Resources

About